Xeris Pharmaceuticals | XERS - Des Atouts





Des Atouts Changement Date
Celltrion KRW 768.81B 9.37B 2026-03
Cspc Pharmaceutical CNY 46.7B 695.56M 2025-12
Deva Holding AS TRY 12.93B 1.83B 2023-09
Dianthus Therapeutics USD 1.25B 715.96M 2026-03
Divis Laboratories Ltd INR 200.33B 18.82B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Kangmei Pharma CNY 13.31B 375.64M 2026-03
Knight Therapeutics CAD 1.05B 2.28M 2025-12
Laboratorios Farma EUR 799.88M 99.95M 2023-12
Malin Corporation EUR 198.5M 70.1M 2024-12
Medical Developments International AUD 63.57M 2.83M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neuren Pharmaceuticals AUD 342.86M 11.61M 2025-12
Organigram Holdings CAD 521.31M 9.36M 2026-03
Ovoca Bio EUR 1.66M 9.75M 2025-06
Pacira USD 1.21B 56.38M 2026-03
Perrigo USD 7.98B 551.9M 2026-03
Pharma Mar EUR 385.26M 9.82M 2026-03
Qiagen NV USD 5.78B 513.9M 2026-03
Sartorius EUR 9.6B 270.6M 2026-06
Sino Biopharmaceutical CNY 74.89B 9.49B 2025-06
Supernus Pharmaceuticals USD 1.5B 48.08M 2026-03
Tilray USD 2.1B 15.95M 2025-09
Zealand Pharma A/S 15.95B 848.45M 2025-12
Zz Pientze Pharmaceu CNY 18.38B 905.93M 2026-03